This Swedish nationwide longitudinal research included 192 sufferers who underwent esophagectomy for most cancers. The publicity was dispositional optimism measured by the Life Orientation Check-Revised (LOT-R) at 1 yr post-surgery. Sufferers have been categorized into 4 subgroups (very low, reasonably low, reasonably excessive, and really excessive dispositional optimism) primarily based on the quartile of the LOT-R sum rating. The result was HRQL assessed by the European Group for Analysis and Therapy of Most cancers High quality of Life Questionnaire-Core 30 and High quality of Life Questionnaire-Esophago-Gastric module 25 at 1, 1.5, and a couple of years post-surgery.
Linear mixed-effects fashions, adjusted for potential confounders, have been used to look at the imply rating distinction (MSD) with 95% confidence interval of HRQL among the many 4 affected person subgroups. Sufferers with very excessive dispositional optimism reported clinically relevantly higher world high quality of life, emotional perform, and social perform (MSD vary 10-16) and fewer extreme signs in ache, dyspnea, diarrhea, consuming problem, anxiousness, dry mouth, bother with style, fear about weight reduction, and self-doubt about physique picture (MSD vary – 9 to – 22) than sufferers with decrease dispositional optimism.
Sufferers with reasonably excessive dispositional optimism reported clinically and statistically considerably higher world high quality of life (MSD 10) and fewer extreme diarrhea (MSD – 9) than sufferers with decrease dispositional optimism. Adjusted MSDs have been fixed over the three time factors in all features aside from consuming problem. Subsequently, the DF-based SA successfully solves the issue of fabric shedding and growing older, thus enhancing the soundness and injury threshold of the fiber laser.
COVID-19: unbalanced administration of occupational risks-case of the evaluation of the chemical threat associated to the usage of disinfectants within the dairy business in Morocco
Moroccan employers have a robust duty for the security and well being of their staff within the office and for shielding them from the chance of COVID-19 and any occupational hazards, as required by Moroccan legislation. As a consequence, industries, together with the agri-food sector, have put in place preventive measures to cope with this pandemic on a number of fronts, together with the usage of hydroalcoholic merchandise and bleach for private and floor disinfection.
These disinfection actions might remove or scale back the chance of coronavirus an infection, however the elevated use of those merchandise by staff may result in critical well being issues and improve the occupational chemical threat within the occasion of uncontrolled publicity. With the intention to analyze this threat within the dairy business in Morocco, we now have launched a qualitative and quantitative research to establish and assess the severity of chemical threat to which its staff are uncovered.
This includes an evaluation of the security information sheets [MSDS] of the disinfectants used and a well being and security survey of the customers of those merchandise, significantly for hand disinfection. This evaluation confirmed that this chemical threat is omnipresent and prevention measures are partially adopted. Certainly, the strengthening of well being security measures to fight COVID-19 has considerably elevated this threat, leading to a outstanding imbalance within the evaluation and administration of occupational dangers on this business.
That is the usage of the Danger Evaluation-Important Management Factors (HACCP)-Instrument for a First Danger Evaluation by Exercise Evaluation (OPERA) method, which we developed and proposed in a earlier research, for a simplified administration of chemical threat within the meals business, particularly in small- and medium-sized enterprises. These outcomes have led us to suggest corrective and preventive measures towards this threat to events and to undertake an built-in administration of meals and occupational well being dangers in a single system.
Monitoring-based deep studying methodology for temporomandibular joint segmentation
The form, measurement, and floor info regarding the glenoid fossae and condyles in temporomandibular joints (TMJ) are important for diagnosing and treating. Sufferers with TMJ illness usually have floor abrasion which can trigger fuzzy edges in computed tomography (CT) imaging, particularly for low-dose CT, making TMJ segmentation harder. On this paper, an computerized segmentation algorithm primarily based on deep studying and post-processing was launched.
First, U-Internet was used to divide photos into three classes: glenoid fossae, condyles, and background. For structural fractures in these divided photos, the inner pressure constraint of a snake mannequin was used to replenish the integrity of the fracture boundary in a post-processing operation, and the preliminary boundary of the snake was obtained primarily based on the idea of the monitoring idea. A complete of 206 instances of low-dose CT have been used to confirm the effectiveness of the algorithm, and such indicators because the Cube coefficient (DC) and imply floor distance (MSD) have been used to judge the settlement between experimental outcomes and the gold normal.
 Anti-CD28 Antibody [CD28.2], APC-100Tests |
|
QAB37-APC-100Tests |
EnQuireBio |
100Tests |
EUR 310.8 |
 Anti-CD28 Antibody [CD28.2], FITC-25Tests |
|
QAB37-F-25Tests |
EnQuireBio |
25Tests |
EUR 157.2 |
 Anti-CD28 Antibody [CD28.2], FITC-100Tests |
|
QAB37-F-100Tests |
EnQuireBio |
100Tests |
EUR 240 |
 Anti-CD28 Antibody [CD28.2], Qfluor 630-100ug |
|
QAB37-QF630-100ug |
EnQuireBio |
100ug |
EUR 259.2 |
 Anti-CD28 Antibody [CD28.2], Unconjugated-100ug |
|
QAB37-100ug |
EnQuireBio |
100ug |
EUR 169.2 |
 Anti-CD28 Antibody [CD28.2], PE-Cy7-25Tests |
|
QAB37-PE7-25Tests |
EnQuireBio |
25Tests |
EUR 199.2 |
 Anti-CD28 Antibody [CD28.2], PerCP-Cy5.5-100Tests |
|
QAB37-PCP55-100Tests |
EnQuireBio |
100Tests |
EUR 381.6 |
 Anti-CD28 Antibody [CD28.2], PerCP-Cy5.5-25Tests |
|
QAB37-PCP55-25Tests |
EnQuireBio |
25Tests |
EUR 229.2 |
 Anti-CD28 Antibody [CD28.2], PE-Cy7-100Tests |
|
QAB37-PE7-100Tests |
EnQuireBio |
100Tests |
EUR 340.8 |
) Anti-CD19/CD22 Bispecific CAR Lentivirus (Clones FMC63/m971 ScFv-CD8-4-1BB-CD3ζ) |
|
78609 |
BPS Bioscience |
50 µl |
EUR 1095 |
|
Description: The anti-CD19/CD22 Bispecific CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragments) of anti-CD19 (clone FMC63) and anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains. |
 Anti-CD3/CD28 stimulus for human PBMC |
|
CT372 |
U-CyTech |
50 tests |
EUR 141.6 |
 Anti-CD28 |
|
E40YR1618 |
EnoGene |
1 mg |
EUR 2960 |
|
Description: Available in various conjugation types. |
 anti-CD28 |
|
YF-PA10780 |
Abfrontier |
50 ug |
EUR 435.6 |
|
Description: Mouse polyclonal to CD28 |
 Hamster Anti CD28 Antibody |
|
20-abx137056 |
Abbexa |
|
|
|
|
 Anti-CD28 Antibody |
|
ER2001-42 |
HUABIO |
100ul |
EUR 189 |
|
|
|
Description: CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival. T cell stimulation through CD28 in addition to the T-cell receptor (TCR) can provide a potent signal for the production of various interleukins (IL-6 in particular). CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins. When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen-presenting cells (APCs). The CD86 expression on antigen-presenting cells is constitutive (expression is independent of environmental factors). CD28 is the only B7 receptor constitutively expressed on naive T cells. Association of the TCR of a naive T cell with MHC:antigen complex without CD28:B7 interaction results in a T cell that is anergic. |
 Anti-CD28 antibody |
|
STJ119563 |
St John's Laboratory |
100 µl |
EUR 332.4 |
|
Description: The protein encoded by this gene is essential for T-cell proliferation and survival, cytokine production, and T-helper type-2 development. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-CD28 antibody |
|
STJ96609 |
St John's Laboratory |
200 µl |
EUR 236.4 |
|
Description: Rabbit polyclonal to CD28. |
Anti-CD28 Antibody |
|
E38A8582 |
EnoGene |
100ug/100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
Anti-CD28 Antibody |
|
E38A8787 |
EnoGene |
100ug/100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
 Hamster Anti CD28 FITC Antibody |
|
20-abx137135 |
Abbexa |
|
|
|
|
 Mouse anti-CD28 Antibody |
|
DL99412A-100ul |
DL Develop |
100 ul |
EUR 299 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
Mouse anti-CD28 Antibody |
|
DL99412A-50ul |
DL Develop |
50 ul |
EUR 210 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
) Anti-CD22 CAR Lentivirus (Clone m971 ScFv-CD8-4-1BB-CD3ζ) |
|
78608 |
BPS Bioscience |
50 µl |
EUR 1095 |
|
Description: The anti-CD22 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (below). |
 Reporter Jurkat Cell Line (CD19 SCFV-CD28 transmembrane motif)) Anti-CD19 CAR negative control/ NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 transmembrane motif) |
|
79854 |
BPS Bioscience |
2 vials |
EUR 1650 |
|
Description: Anti-CD19 CAR negative control/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR negative control and NFAT-luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without any intracellular signaling domains. The reporter cell line has been validated for anti- CD19 expression by FACS, while the stimulation by target cells including CD19/CHO recombinant cell line has not activated the luciferase reporter gene in this cell line. The cell line can be used for the negative control of anti-CD19 CAR/Jurkat-NFAT cell line (BPS Bioscience, #79853)._x000D_ _x000D_ |
 Anti-CD28 Agonist Antibody |
|
100182-1 |
BPS Bioscience |
50 µg |
EUR 335 |
|
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody crosslinked with FcGR2B is useful for activation of CD27 costimulatory pathway in T cells. |
Anti-CD28 Agonist Antibody |
|
100182-2 |
BPS Bioscience |
100 µg |
EUR 460 |
|
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. |
 Hamster Anti CD28 Biotinylated Antibody |
|
20-abx137134 |
Abbexa |
|
|
|
|
) Anti-CD20 CAR Lentivirus (Clone Leu-16 ScFv-CD8-4-1BB-CD3ζ) |
|
78606 |
BPS Bioscience |
50 µl |
EUR 1095 |
|
Description: The anti-CD20 CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragment) of anti-CD20 (clone Leu-16) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains . |
 Antibody) Rabbit anti-CD28 (pY218) Antibody |
|
DL90184A-100ul |
DL Develop |
100 ul |
EUR 299 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
Rabbit anti-CD28 (pY218) Antibody |
|
DL90184A-50ul |
DL Develop |
50 ul |
EUR 209.3 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
Rabbit anti-CD28 (pY218) Antibody |
|
YLD1497-100ul |
Shanghai YL Biotech |
100 ul |
EUR 320 |
|
|
|
Description: Rabbit polyclonal antibody to CD28 (pY218) |
Rabbit anti-CD28 (pY218) Antibody |
|
YLD1497-50ul |
Shanghai YL Biotech |
50 ul |
EUR 200 |
|
|
|
Description: Rabbit polyclonal antibody to CD28 (pY218) |
 Syrian Hamster anti-CD28 Antibody |
|
DL99429A-100ul |
DL Develop |
100 ul |
EUR 299 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
Syrian Hamster anti-CD28 Antibody |
|
DL99429A-50ul |
DL Develop |
50 ul |
EUR 210 |
|
|
|
Description: T-cell-specific surface glycoprotein CD28; TP44; CD28 |
) Anti-CD28 Reference Antibody (FR104) |
|
E24CHA679 |
EnoGene |
100 μg |
EUR 225 |
|
Description: Available in various conjugation types. |
) Anti-CD30 / TNFRSF8 Antibody (CD30/412) |
|
A1484-100 |
Biovision |
each |
EUR 574.8 |
) Anti-CD28 Agonist Antibody (Humanized) |
|
100186-1 |
BPS Bioscience |
50 µg |
EUR 345 |
|
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody crosslinked with FcGR2B is useful for activation of CD27 costimulatory pathway in T cells. This antibody has been humanized to reduce immunogenicity and improve the therapeutic half-life. |
Anti-CD28 Agonist Antibody (Humanized) |
|
100186-2 |
BPS Bioscience |
100 µg |
EUR 475 |
|
Description: Recombinant monoclonal antibody recognizing human CD28. This antibody binds to CD28 on T cells and promotes T cell response. Not tested in other species. This antibody has been humanized to reduce immunogenicity and improve the therapeutic half-life. |
 Anti-CD40/Cd40 Antibody |
|
A00068-1 |
BosterBio |
100ug/vial |
EUR 352.8 |
 Anti-CD16+CD32 antibody |
|
MO16A(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16A(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16B(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16B(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16CFB(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16CFB(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16F(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16F(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16F(V500) |
ImmunoStep |
500 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PE(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PE(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PP(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PP(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PP5.5(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PP5.5(V25) |
ImmunoStep |
25 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PU(V100) |
ImmunoStep |
100 ug |
EUR 60 |
Anti-CD16+CD32 antibody |
|
MO16PU(V500) |
ImmunoStep |
500 ug |
EUR 60 |
 Anti-CD16/CD32 Antibody |
|
E38A8954 |
EnoGene |
100ug/100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
 Anti-CD59/Cd59a Antibody |
|
A00914 |
BosterBio |
100ug/vial |
EUR 400.8 |
 Anti-CD70/Cd27L Antibody |
|
A02853 |
BosterBio |
100ul |
EUR 476.4 |
|
Description: Rabbit Polyclonal CD70/Cd27L Antibody. Validated in WB and tested in Human. |
 Rat anti-CD16/CD32 Antibody |
|
DL99452A-100ul |
DL Develop |
100 ul |
EUR 299 |
|
|
|
Description: CD32; FCG2; IGFR2; Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; CDw32; Fc-gamma RII-b; Fc-gamma-RIIb; FcRII-b; CD32 |
Rat anti-CD16/CD32 Antibody |
|
DL99452A-50ul |
DL Develop |
50 ul |
EUR 210 |
|
|
|
Description: CD32; FCG2; IGFR2; Low affinity immunoglobulin gamma Fc region receptor II-b; IgG Fc receptor II-b; CDw32; Fc-gamma RII-b; Fc-gamma-RIIb; FcRII-b; CD32 |
 Anti-CD40L/CD40LG Antibody |
|
A01114-1 |
BosterBio |
100ug/vial |
EUR 352.8 |
 Anti-CD40L/Cd40lg Antibody |
|
A01114-2 |
BosterBio |
100ug/vial |
EUR 400.8 |
Anti-CD40L/CD40LG Antibody |
|
A01114-3 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-CD40L/CD40LG Antibody |
|
PA1020 |
BosterBio |
100ug/vial |
EUR 400.8 |
 Anti-CD16/CD32, Rat IgG2b Antibody |
|
A1106-200 |
Biovision |
each |
EUR 874.8 |
-MC-MMAF ADC) Anti-CD28 (lumretuzumab)-MC-MMAF ADC |
|
ADC-W-2278 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a MC linker to MMAF |
 Anti-CD16/CD32, Rabbit IgG Antibody |
|
A1107-200 |
Biovision |
each |
EUR 874.8 |
-SMCC-DM1 ADC) Anti-CD28 (lumretuzumab)-SMCC-DM1 ADC |
|
ADC-W-2276 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a SMCC linker to DM1 |
-SPDB-DM4 ADC) Anti-CD28 (lumretuzumab)-SPDB-DM4 ADC |
|
ADC-W-2277 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a SPDB linker to DM4 |
) Recombinant Anti-CD33 x Anti-CD16 x CD123 Trispecific Antibody (Single-chain Triplebody) |
|
SCTB-104 |
Creative Biolabs |
200μg |
Ask for price |
|
Description: A trispecific antibody that is expressed as a single chain with three scFv units, two distal binding sites for CD33 and CD123, a central site for CD16. This BsAb can retarget NK cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML) therapy. |
) Anti-OX2R / CD200R1 Reference Antibody (Janssen anti-CD200R1) |
|
E24CHA149 |
EnoGene |
100 μg |
EUR 225 |
|
Description: Available in various conjugation types. |
) Anti-EMMPRIN / CD147 Reference Antibody (Centocor anti-CD147) |
|
E24CHA651 |
EnoGene |
100 μg |
EUR 225 |
|
Description: Available in various conjugation types. |
 Anti-CD28 Antibody [37.51], Unconjugated-25ug |
|
QAB99-25ug |
EnQuireBio |
25ug |
EUR 138 |
) Anti-CD44v4 Antibody (Clone CD44v4/1219) |
|
A1526-100 |
Biovision |
each |
EUR 574.8 |
) Anti-CD44v6 Antibody (Clone CD44v6/1246) |
|
A1527-100 |
Biovision |
each |
EUR 574.8 |
) Anti-CD44v9 Antibody (Clone CD44v9/1459) |
|
A1528-100 |
Biovision |
each |
EUR 574.8 |
 Anti-CD28 Antibody [37.51], Unconjugated-100ug |
|
QAB99-100ug |
EnQuireBio |
100ug |
EUR 178.8 |
 Anti-CD28 Antibody [37.51], Unconjugated-500ug |
|
QAB99-500ug |
EnQuireBio |
500ug |
EUR 279.6 |
 Anti-CD28 Antibody [37.51], Qfluor 630-100ug |
|
QAB99-QF630-100ug |
EnQuireBio |
100ug |
EUR 270 |
 Anti-CD28 Antibody [37.51], Qfluor 630-500ug |
|
QAB99-QF630-500ug |
EnQuireBio |
500ug |
EUR 372 |
-MC-MMAF ADC) Anti-CD28 (lulizumab pegol)-MC-MMAF ADC |
|
ADC-W-2332 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a MC linker to MMAF |
 resDetect™ Anti-CD28 Antibody ELISA Kit |
|
CRS-A014 |
ACROBIOSYSTEMS |
96tests |
EUR 652.7 |
|
|
|
Description: Similar to CD3 antibody, CD28 antibodies also can be used to stimulate the proliferation and activation of T cells in CIK cell therapy. Under the cooperation of other cytokines, such as IL2 and IL1a, CIK cells with rapid proliferation, high tumoricidal activity, broad tumor killing spectrum and non-MHC-restricted tumor killing characteristics are generated，which has significant effects on the treatment of cancer, chronic leukemia, liver disease and neurological diseases. Obviously, It is necessary to control the residues of raw materials in the final cell therapy products. |
-SMCC-DM1 ADC) Anti-CD28 (lulizumab pegol)-SMCC-DM1 ADC |
|
ADC-W-2330 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a SMCC linker to DM1 |
-SPDB-DM4 ADC) Anti-CD28 (lulizumab pegol)-SPDB-DM4 ADC |
|
ADC-W-2331 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a SPDB linker to DM4 |
 Anti-CD30/ TNFRSF8 Antibody Clone CD30/412, Unconjugated-20ug |
|
943-MSM1-P0 |
EnQuireBio |
20ug |
EUR 279.6 |
) Anti-CD11c Monoclonal Antibody (CD11C-100/D2) |
|
CTA-228-100ug |
Creative Biolabs |
100ug |
Ask for price |
|
Description: Mouse anti-CD11c monoclonal antibody (CD11C-100/D2) for WB, IP. |
Anti-CD11c Monoclonal Antibody (CD11C-100/D2) |
|
CTA-228-1mg |
Creative Biolabs |
1mg |
Ask for price |
|
Description: Mouse anti-CD11c monoclonal antibody (CD11C-100/D2) for WB, IP. |
 Anti-CD30/ TNFRSF8 Antibody Clone CD30/412, Unconjugated-100ug |
|
943-MSM1-P1 |
EnQuireBio |
100ug |
EUR 513.6 |
) Anti-CD23 (S52) |
|
YF-MA12968 |
Abfrontier |
50 ug |
EUR 435.6 |
|
Description: Mouse monoclonal to CD23 |
) Anti-CD23 (S51) |
|
YF-MA12969 |
Abfrontier |
200 ul |
EUR 435.6 |
|
Description: Mouse monoclonal to CD23 |
) Anti-CD28L / CD80 Reference Antibody (galiximab) |
|
E24CHA680 |
EnoGene |
100 μg |
EUR 225 |
|
Description: Available in various conjugation types. |
 Anti-CD68 Antibody Clone CD68/G2, Unconjugated-100ug |
|
968-MSM5-P1 |
EnQuireBio |
100ug |
EUR 513.6 |
) Anti-TNFRSF5 / CD40 Reference Antibody (Emory U. anti-CD40) |
|
E24CHA741 |
EnoGene |
100 μg |
EUR 225 |
|
Description: Available in various conjugation types. |
) Anti-PTPRC / CD45 Reference Antibody (Novartis anti-CD45) |
|
E24CHA929 |
EnoGene |
100 μg |
EUR 225 |
|
Description: Available in various conjugation types. |
-MC-Vc-PAB-MMAE ADC) Anti-CD28 (lumretuzumab)-MC-Vc-PAB-MMAE ADC |
|
ADC-W-2279 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a MC-Vc linker to MMAE |
-MC-Vc-PAB-SN38 ADC) Anti-CD28 (lumretuzumab)-MC-Vc-PAB-SN38 ADC |
|
ADC-W-2280 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38 |
) Anti-TNFRSF7 / CD27 Reference Antibody (Organon anti-CD27) |
|
E24CHB002 |
EnoGene |
100 μg |
EUR 225 |
|
Description: Available in various conjugation types. |
 Anti-CD44v4 Antibody Clone CD44v4/1219, Unconjugated-20ug |
|
960-MSM6-P0 |
EnQuireBio |
20ug |
EUR 279.6 |
 Anti-CD44v6 Antibody Clone CD44v6/1246, Unconjugated-20ug |
|
960-MSM7-P0 |
EnQuireBio |
20ug |
EUR 279.6 |
 Anti-CD44v9 Antibody Clone CD44v9/1459, Unconjugated-20ug |
|
960-MSM8-P0 |
EnQuireBio |
20ug |
EUR 279.6 |
 Anti-CD44v4 Antibody Clone CD44v4/1219, Unconjugated-100ug |
|
960-MSM6-P1 |
EnQuireBio |
100ug |
EUR 513.6 |
 Anti-CD44v6 Antibody Clone CD44v6/1246, Unconjugated-100ug |
|
960-MSM7-P1 |
EnQuireBio |
100ug |
EUR 513.6 |
 Anti-CD44v9 Antibody Clone CD44v9/1459, Unconjugated-100ug |
|
960-MSM8-P1 |
EnQuireBio |
100ug |
EUR 513.6 |
 Anti-CD44v4 Antibody Clone CD44v4/1700R, Unconjugated-20ug |
|
960-RBM10-P0 |
EnQuireBio |
20ug |
EUR 279.6 |
 Anti-CD44v4 Antibody Clone CD44v4/1700R, Unconjugated-100ug |
|
960-RBM10-P1 |
EnQuireBio |
100ug |
EUR 513.6 |
 Anti-CD37-SMCC-DM1 ADC |
|
ADC-W-473 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an Anti-CD37 antibody conjugated via a SMCC linker to DM1 |
 (Rabbit IgGκ)) Anti-CD35/CD21 Recombinant Monoclonal Antibody (7G6) (Rabbit IgGκ) |
|
CTA-041-100ug |
Creative Biolabs |
100ug |
Ask for price |
|
Description: Mouse anti-CD35/CD21 recombinant monoclonal antibody (7G6) (Rabbit IgGκ) for Flow Cytometry, IHC (FS), IP, WB, FUNC. |
Anti-CD35/CD21 Recombinant Monoclonal Antibody (7G6) (Rabbit IgGκ) |
|
CTA-041-1mg |
Creative Biolabs |
1mg |
Ask for price |
|
Description: Mouse anti-CD35/CD21 recombinant monoclonal antibody (7G6) (Rabbit IgGκ) for Flow Cytometry, IHC (FS), IP, WB, FUNC. |
-MC-Vc-PAB-MMAE ADC) Anti-CD28 (lulizumab pegol)-MC-Vc-PAB-MMAE ADC |
|
ADC-W-2333 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a MC-Vc linker to MMAE |
-MC-Vc-PAB-SN38 ADC) Anti-CD28 (lulizumab pegol)-MC-Vc-PAB-SN38 ADC |
|
ADC-W-2334 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a MC-Vc-PAB linker to SN38 |
 Recombinant Mouse Anti-CD28 monoclonal antibody, clone D665 |
|
CABT-L1150 |
Creative Diagnostics |
200ug |
EUR 1164 |
 Anti-CD2/CD2 Antibody |
|
PB9929 |
BosterBio |
100ug/vial |
EUR 400.8 |
Anti-CD2/CD2 Antibody |
|
PA1743 |
BosterBio |
100ug/vial |
EUR 352.8 |
) Polyclonal Goat Anti-CD3-ZETA / CD247 Antibody (internal region) |
|
APG00963G |
Leading Biology |
0.1mg |
EUR 580.8 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-CD3-ZETA / CD247 (internal region). This antibody is tested and proven to work in the following applications: |
 anti-CDS2 |
|
YF-PA25174 |
Abfrontier |
50 ul |
EUR 400.8 |
|
Description: Mouse polyclonal to CDS2 |
) Anti-CDS2 (2B9) |
|
YF-MA16505 |
Abfrontier |
100 ug |
EUR 435.6 |
|
Description: Mouse monoclonal to CDS2 |
) Anti-CDCP1 / CD318 Reference Antibody (U.California anti-CDCP1) |
|
E24CHA172 |
EnoGene |
100 μg |
EUR 225 |
|
Description: Available in various conjugation types. |
 Anti-CD8 alpha/Cd8a Antibody |
|
A02236-1 |
BosterBio |
100ug/vial |
EUR 400.8 |
Anti-CD8 alpha/Cd8a Antibody |
|
A02236-2 |
BosterBio |
100ug/vial |
EUR 400.8 |
 Anti-CD8 alpha/CD8A Antibody |
|
PB9249 |
BosterBio |
100ug/vial |
EUR 400.8 |
) Anti-CDS1 (2D10) |
|
YF-MA12394 |
Abfrontier |
100 ug |
EUR 435.6 |
|
Description: Mouse monoclonal to CDS1 |
 Anti-CD5 Antibody Clone C5/473 + CD5/54/F6, Unconjugated-100ug |
|
921-MSM3-P1 |
EnQuireBio |
100ug |
EUR 513.6 |
 Anti-CD3 epsilon/Cd3e Antibody |
|
A02675 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-CD3 epsilon/Cd3e Antibody |
|
A02765-1 |
BosterBio |
100ug/vial |
EUR 400.8 |
Anti-CD3 epsilon/Cd3e Antibody |
|
A02765-2 |
BosterBio |
100ug/vial |
EUR 400.8 |
 Anti-CD3 epsilon/CD3E Antibody |
|
PB9093 |
BosterBio |
100ug/vial |
EUR 400.8 |
Anti-CD3 epsilon/CD3E Antibody |
|
PA2264 |
BosterBio |
100ug/vial |
EUR 352.8 |
-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC) Anti-CD28 (lumretuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC |
|
ADC-W-2281 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA |
 Anti-CDS2 antibody |
|
STJ26590 |
St John's Laboratory |
100 µl |
EUR 332.4 |
|
Description: Breakdown products of phosphoinositides are ubiquitous second messengers that function downstream of many G protein-coupled receptors and tyrosine kinases regulating cell growth, calcium metabolism, and protein kinase C activity. This gene encodes an enzyme which regulates the amount of phosphatidylinositol available for signaling by catalyzing the conversion of phosphatidic acid to CDP-diacylglycerol. This enzyme is an integral membrane protein localized to two subcellular domains, the matrix side of the inner mitochondrial membrane where it is thought to be involved in the synthesis of phosphatidylglycerol and cardiolipin and the cytoplasmic side of the endoplasmic reticulum where it functions in phosphatidylinositol biosynthesis. Two genes encoding this enzyme have been identified in humans, one mapping to human chromosome 4q21 and a second to 20p13. |
 Anti-CDS1 antibody |
|
STJ115706 |
St John's Laboratory |
100 µl |
EUR 332.4 |
|
Description: Breakdown products of phosphoinositides are ubiquitous second messengers that function downstream of many G protein-coupled receptors and tyrosine kinases regulating cell growth, calcium metabolism, and protein kinase C activity. This gene encodes an enzyme which regulates the amount of phosphatidylinositol available for signaling by catalyzing the conversion of phosphatidic acid to CDP-diacylglycerol. This enzyme is an integral membrane protein localized to two subcellular domains, the matrix side of the inner mitochondrial membrane where it is thought to be involved in the synthesis of phosphatidylglycerol and cardiolipin and the cytoplasmic side of the endoplasmic reticulum where it functions in phosphatidylinositol biosynthesis. Two genes encoding this enzyme have been identified in humans, one mapping to human chromosome 4q21 and a second to 20p13. |
-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC) Anti-CD28 (lulizumab pegol)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC |
|
ADC-W-2335 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-CD28 Monovalent antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA |
 polyclonal antibody) CD28 antigen (CD28) polyclonal antibody |
|
ABP-PAB-10144 |
Allele Biotech |
100 ug |
Ask for price |
|
|
 Anti-CDSN antibody |
|
STJ116779 |
St John's Laboratory |
100 µl |
EUR 332.4 |
|
Description: This gene encodes a protein found in corneodesmosomes, which localize to human epidermis and other cornified squamous epithelia. The encoded protein undergoes a series of cleavages during corneocyte maturation. This gene is highly polymorphic in human populations, and variation has been associated with skin diseases such as psoriasis, hypotrichosis and peeling skin syndrome. The gene is located in the major histocompatibility complex (MHC) class I region on chromosome 6. |
Anti-CDSN antibody |
|
STJ116812 |
St John's Laboratory |
100 µl |
EUR 332.4 |
|
Description: This gene encodes a protein found in corneodesmosomes, which localize to human epidermis and other cornified squamous epithelia. The encoded protein undergoes a series of cleavages during corneocyte maturation. This gene is highly polymorphic in human populations, and variation has been associated with skin diseases such as psoriasis, hypotrichosis and peeling skin syndrome. The gene is located in the major histocompatibility complex (MHC) class I region on chromosome 6. |
 PE mouse anti-Chicken CD28 |
|
E16FCP028-100U |
EnoGene |
0.1 mg |
EUR 931.67 |
|
Description: Available in various conjugation types. |
 Mouse mAb) Anti-CD54 (ICAM-1) Mouse mAb |
|
E2200350-D6 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
 CD28 antibody |
|
10R-6375 |
Fitzgerald |
100 ug |
EUR 230.4 |
|
Description: Syrian Hamster monoclonal CD28 antibody |
CD28 antibody |
|
10R-6376 |
Fitzgerald |
100 ug |
EUR 230.4 |
|
Description: Mouse monoclonal CD28 antibody |
CD28 antibody |
|
10R-CD28bHU |
Fitzgerald |
100 ul |
EUR 560.4 |
|
Description: Mouse monoclonal CD28 antibody |
CD28 antibody |
|
10R-CD28dCKp |
Fitzgerald |
500 ug |
EUR 483.6 |
|
Description: Mouse monoclonal CD28 antibody |
CD28 antibody |
|
10R-CD28dMS |
Fitzgerald |
500 ug |
EUR 444 |
|
Description: Hamster monoclonal CD28 antibody |
CD28 antibody |
|
10R-CD28eMS |
Fitzgerald |
500 ug |
EUR 444 |
|
Description: Hamster monoclonal CD28 antibody |
 CD28 Antibody |
|
8683-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
|
|
Description: N/A |
CD28 Antibody |
|
8683-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
|
|
Description: N/A |
CD28 antibody |
|
70R-CR045 |
Fitzgerald |
100 ug |
EUR 360 |
|
Description: Affinity purified Rabbit polyclonal CD28 antibody |
CD28 antibody |
|
70R-9669 |
Fitzgerald |
50 ug |
EUR 560.4 |
|
Description: Affinity purified rabbit polyclonal CD28 antibody |
CD28 antibody |
|
70R-49503 |
Fitzgerald |
100 ul |
EUR 344.4 |
|
Description: Purified Polyclonal CD28 antibody |
CD28 Antibody |
|
46435-100ul |
SAB |
100ul |
EUR 302.4 |
CD28 Antibody |
|
1-CSB-PA005199 |
Cusabio |
|
|
|
|
|
Description: A polyclonal antibody against CD28. Recognizes CD28 from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000 |
CD28 Antibody |
|
F49999-0.08ML |
NSJ Bioreagents |
0.08 ml |
EUR 140.25 |
|
Description: CD28 costimulation is essential for CD4-positive T-cell proliferation, survival, interleukin-2 production, and T-helper type-2 (Th2) development. |
CD28 Antibody |
|
F49999-0.4ML |
NSJ Bioreagents |
0.4 ml |
EUR 322.15 |
|
Description: CD28 costimulation is essential for CD4-positive T-cell proliferation, survival, interleukin-2 production, and T-helper type-2 (Th2) development. |
CD28 Antibody |
|
R36029-100UG |
NSJ Bioreagents |
100 ug |
EUR 339.15 |
|
Description: Additional name(s) for this target protein: T-cell-specific surface glycoprotein CD28 antibody |
 Cd28 Antibody |
|
R34402-100UG |
NSJ Bioreagents |
100 ug |
EUR 339.15 |
|
Description: Additional name(s) for this target protein: T-cell-specific surface glycoprotein CD28 antibody |
Utility of the SA in erbium-doped fiber laser and steady passive Q-switched operation with a most pulse power of 430.47 nJ is realized. By adjusting the polarization state and pump energy, high-power mode-locked pulses are generated with a pulse period and output energy of 199 fs and 54.13 mW, respectively. Additional, bound-state soliton pulses are obtained with a pulse width of 312 fs and soliton interval of 1.26 ps for the primary time primarily based on MXene supplies. Furthermore, by utility of the SA in ytterbium-doped fiber lasers, a steady dissipative soliton mode-locked pulse is obtained with a pulse width of 23 ps. These outcomes point out that the DF-based buried Mo2C as a novel SA offers a dependable methodology for all-fiber and multifunctional high-power ultrafast laser.
